Mont-Royal, Canada Clinical Trials

A listing of Mont-Royal, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 109 clinical trials
Featured trial
Caregiver-Provided Life Review for Persons with Dementia

This study, Caregiver-Provided Life Review (C-PLR) is created based on Life Review therapy. It is for persons living with early-stage dementia along with mild depressive symptoms who are 65 years or older, community-dwellers or the residents of senior housing, independent or assisted living facilities conducted by their family members (18 …

Online studies
Accepts healthy volunteers
dementia
depression
Online Study Center
(online study) Contact site
  • 566 views
  • 09 Aug, 2022
  • 1 location
  • Online study
Featured trial
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

H pital Maisonneuve-Rosemont /ID# 221925
 (4.8 away) Contact site
  • 380 views
  • 11 Aug, 2022
  • +149 other locations
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

McGill University Health Center Research Institute /ID# 222614
 (2.3 away) Contact site
  • 835 views
  • 10 Aug, 2022
  • +225 other locations
Featured trial
Integument-1 study

We are currently recruiting pediatric and adult patients with mild to moderate atopic dermatitis (eczema) for a study that investigates the safety and efficacy of the ARQ-151 cream. 

Innovaderm Research
 (0.9 away) Contact site
  • 34 views
  • 15 Aug, 2022
  • +54 other locations
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have …

enfortumab vedotin
metastatic urothelial carcinoma
pd-l1
carboplatin
systemic therapy
Site CA11010
 (1.6 away) Contact site
  • 121 views
  • 11 Aug, 2022
  • +190 other locations
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Primary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine Secondary Objectives: To demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU disease control To demonstrate the efficacy …

Investigational Site Number :1240011
 (2.4 away) Contact site
  • 58 views
  • 10 Aug, 2022
  • +29 other locations
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, …

McGill University Health Centre
 (0.2 away) Contact site
  • 93 views
  • 08 Aug, 2022
  • +172 other locations
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause (Daylight)

This study is for women in menopause who have moderate to severe hot flashes. It is for women who are unable to use hormone replacement therapy (HRT). Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt …

Site CA15012
 (5.6 away) Contact site
  • 25 views
  • 11 Aug, 2022
  • +89 other locations
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

The purpose of this study is to assess the efficacy of lazertinib, amivantamab, carboplatin, and pemetrexed (LACP) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP), respectively, in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small …

epidermal growth factor
osimertinib
carboplatin
squamous non-small cell lung cancer
growth factor
McGill University Health Centre
 (0.2 away) Contact site
  • 11 views
  • 10 Aug, 2022
  • +207 other locations
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by …

Clinical Trial Site
 (0.3 away) Contact site
  • 0 views
  • 10 Aug, 2022
  • +49 other locations